Zymeworks Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin

Zymeworks Inc. (NYSE:ZYME) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $17.63 and last traded at $17.83, with a volume of 5775 shares trading hands. The stock had previously closed at $18.49. ZYME has been the subject of several research analyst reports. HC Wainwright restated a […]

Equities analysts expect that Zymeworks Inc. (NYSE:ZYME) will announce earnings per share (EPS) of ($1.10) for the current quarter, Zacks reports. Five analysts have issued estimates for Zymeworks earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($0.92). Zymeworks reported earnings per share of ($0.74) in the []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Thrivent Financial for Lutherans increased its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 2.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 322,364 shares of the companys stock after buying an additional 7,547 shares during the quarter. Thrivent Financial for []

In last trading session, Zymeworks Inc. (NYSE:ZYME) saw 0.48 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $18.49 trading at -$1.75 or -8.65% at ring of the bell on the day assigns it a market valuation of $841.66M. That closing price of ZYME’s stock is at … Does Zymeworks Inc. (NYSE:ZYME) Look Expensive At $18.49? Here’s How To Know. Read More »

Vigilare Wealth Management acquired a new stake in Zymeworks Inc. (NYSE:ZYME) during the third quarter, according to its most recent filing with the SEC. The firm acquired 10,200 shares of the companys stock, valued at approximately $296,000. A number of other institutional investors have also added to or reduced their stakes in ZYME. Cutler Group []

This move is a reversal from the hour prior, which saw price move up. The post Zymeworks Inc (ZYME): Price Now Near $20.12; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .

Wall Street brokerages expect Zymeworks Inc. (NYSE:ZYME) to report $11.19 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Zymeworks earnings, with the highest sales estimate coming in at $22.00 million and the lowest estimate coming in at $2.50 million. Zymeworks posted sales of $15.68 million in the []

Zymeworks Inc. (NYSE:ZYME) traded at $19.38 at close of the session on Monday, 11/29/21, made a downward move of -0.62% on its previous days price. Looking at the stock we see that its previous close was $19.50 and the beta (5Y monthly) reads 0.97 with the days price range being $19.26 $20.00. In terms Why Zymeworks Inc. Stock Might Make Sense If Bought Today Read More »

Vanguard Group Inc. raised its stake in Zymeworks Inc. (NYSE:ZYME) by 26.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,214 shares of the companys stock after buying an additional 34,969 shares during the period. Vanguard Group Inc.s holdings in Zymeworks were worth []